Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Escalate
Acute limb ischaemia is a vascular emergency. New sensory loss or weakness means an immediately threatened limb: contact a vascular specialist at once, give unfractionated heparin unless contraindicated and transfer for urgent revascularisation.
Synopsis
Identify a suddenly threatened limb, grade viability and start time-critical anticoagulation and vascular treatment without avoidable imaging delay.
ALI is a sudden fall in limb perfusion, usually within 14 days, that threatens tissue viability.
The six Ps—pain, pallor, pulselessness, perishing cold, paraesthesia and paralysis—describe the syndrome, but an incomplete set does not exclude it.
Neurological deficit drives urgency: paraesthesia and especially motor weakness indicate a threatened limb.
Key red flags
Rutherford IIa—marginally threatened
Minimal sensory loss, usually toes, with no motor deficit; salvageable if treated promptly.
Investigation priorities
01
Immediate serial neurovascular examination with hand-held DopplerFirst step
Grade limb viability and detect deterioration.
Management branches
first minutesSuspected ALI
Sudden limb pain/coldness, pulse loss, sensory change or weakness.
First: assess ABCs, note exact onset, examine both limbs and document Doppler, sensation and motor power; give analgesia and keep the patient nil by mouth.
Next: contact the on-call vascular specialist immediately and arrange transfer to a centre offering open and endovascular treatment.
Key medicines
Unfractionated heparin5,000 units IV bolus, or 70–100 units/kg IV, followed by an IV infusion adjusted to APTT or ACT response.
MorphineOne licensed injection regimen uses 2.5–10 mg IV, injected slowly over 4–5 minutes; select the lowest effective dose and titrate any further dosing to response in a monitored setting.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.